J&J-backed Bright Peak secures $90m to advance immunoconjugate program

Bright Peak Therapeutics has raised $90m in a Series C financing round as the biotech looks to make a name for itself in the immunoconjugate space.

Johnson and Johnson’s (J&J) investment arm JJDC led the Series C round backing Bright Peak’s cancer treatment portfolio, which also saw participation from new investors Venrock, KB Investment, and Northleaf Capital Partners.